Pharmacy and Pharmaceutical Sciences Commons^™

Daptomycin Non-Susceptible Mrsa Bacteremia: A Case Report, Jaclyn Cusumano, Pharmd, Anna Marie Morlino, Pharmd, Andrew Moyer, Pharmd

College of Pharmacy Posters

Background

Staphylococcus aureus^{1, 2, 3}

• One of the most common pathogens causing community-acquired and nosocomial infections
• Has rapidly developed resistance to many antibiotics:

Daptomycin ²

• Bactericidal cyclic lipopeptide antibiotic
• Possesses negative charge which attracts calcium to form cationic complex
• Interacts with negatively charged phospholipid heads on bacterial cell membranes, leading to membrane depolarization and cell death

Daptomycin non-susceptible (DNS) S. aureus ^{2, 4, 5}

• Extremely rare - About 60 clinical cases reported
• Defined by an MIC greater than 1 mcg/mL
• Potential mechanisms include:

– Changes in cell membrane and cell wall structure alter daptomycin’s permeability²

• Overexpression and dysregulation …

A Phase I Study Of Ad5-Gucy2c-Padre In Stage I And Ii Colon Cancer Patients, Adam E. Snook, Trevor R. Baybutt, Michael J. Mastrangelo, Nancy L. Lewis, Scott D. Goldstein, Walter K. Kraft, Yaa D. Oppong, Terry Hyslop, Ronald E. Myers, Vitali Alexeev, Laurence C. Eisenlohr, Takami Sato, Scott A. Waldman

Department of Pharmacology and Experimental Therapeutics Posters

Background

Ad5-GUCY2C-PADRE is a replication-deficient human type 5 recombinant adenovirus (Ad5) vaccine encoding guanylyl cyclase C (GUCY2C) fused to the PAn DR Epitope (PADRE). GUCY2C, a paracrine hormone receptor producing the second messenger cyclic GMP (cGMP), is selectively expressed by intestinal epithelial cells and a subset of hypothalamic neurons, but not other tissues. Importantly, GUCY2C is over-expressed in nearly all primary and metastatic human colorectal tumors. Preclinical studies in mice demonstrated selective tolerance of GUCY2C-specific CD4+ T cells, but not CD8+ T or B cells, necessitating inclusion of the exogenous CD4+ T helper cell epitope PADRE to maximize GUCY2C-specific CD8+ …

Ethanol Pharmacokinetics In Neonates Secondary To Medication Administration, Elizabeth Marek, Pharmd, Susan C. Adeniyi-Jones, Md, Lindsey Roke, Pharmd, Tara E. Decerbo, Pharmd, Rebecca L. Cordell, Pharmd, Paul S. Monks, Pharmd, Walter K. Kraft, Md

Department of Pharmacology and Experimental Therapeutics Posters

Purpose:

Ethanol serves as a solvent and microbial preservative in oral liquid medications and is the second most commonly used solvent in liquid medications following water. Despite widespread use of ethanol in liquid medications for neonates, the pharmacokinetics and toxicity of ethanol in young children are not well described. The aim of the current study is to quantify blood ethanol levels in neonates secondary to oral ethanol containing medications.

Methods:

Neonates who received either oral phenobarbital (15% ethanol) and/or oral dexamethasone (30% ethanol) per standard of care were eligible for enrollment. A maximum of 6 blood samples per patient (4.5 …